City of Hope (T Cell Manufacturing) vs Eurofins CDMO: CDMO Comparison
Side-by-side comparison of City of Hope (T Cell Manufacturing) and Eurofins CDMO on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- City of Hope (T Cell Manufacturing) appears as a manufacturing partner on more matched clinical programs (209 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both City of Hope (T Cell Manufacturing) and Eurofins CDMO qualify as Cell Therapy manufacturers; City of Hope (T Cell Manufacturing) carries the higher composite Signal Score for Cell Therapy programs in this comparison.
What to evaluate for Cell Therapy programs
Both City of Hope (T Cell Manufacturing) and Eurofins CDMO qualify as Cell Therapy CDMOs. When choosing between them for Cell Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Autologous vs allogeneic
Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.
Vector & raw materials
Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.
Closed-system & cleanrooms
Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.
Cold chain & logistics
Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.
Frequently asked: City of Hope (T Cell Manufacturing) vs Eurofins CDMO
Which has the stronger FDA inspection record, City of Hope (T Cell Manufacturing) or Eurofins CDMO?
Both City of Hope (T Cell Manufacturing) and Eurofins CDMO maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. City of Hope (T Cell Manufacturing) has 3 FDA inspections on record; Eurofins CDMO has 4.
Which is more active in clinical-stage manufacturing — City of Hope (T Cell Manufacturing) or Eurofins CDMO?
City of Hope (T Cell Manufacturing) is matched to 209 ClinicalTrials.gov records as a manufacturing partner; Eurofins CDMO is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Cell Therapy manufacturing — City of Hope (T Cell Manufacturing) or Eurofins CDMO?
Both City of Hope (T Cell Manufacturing) and Eurofins CDMO are tagged as Cell Therapy CDMOs in our directory, so both are credible options for Cell Therapy programs. The most important differentiator for Cell Therapy selection is typically autologous vs allogeneic: Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
City of Hope (T Cell Manufacturing) carries a Signal Score of 84/100 and Eurofins CDMO carries 82/100 — essentially tied for City of Hope (T Cell Manufacturing). The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →